#cardiovascular-risk

#cardiovascular-risk

A large study led by scientists at McMaster University has found that fat stored deep inside the abdomen and liver can quietly injure arteries, even in people who seem healthy on the outside. The research, published on October 17, 2025, in Communications Medicine, questions the long-standing use of body-mass index (BMI) as a reliable indicator of obesity and heart risk. It offers new evidence that the fat people cannot see may be just as dangerous as the weight they can.

To collect wine, or any alcohol, is to curate not only bottles but stories, memories, and aspirations. A cellar becomes a gallery of taste and time: a 1990 Bordeaux resting beside a Sonoma Pinot Noir, each label recalling moments of celebration, of refinement, even of restraint. Collectors often speak of wine as a living art, something to be admired and shared, not merely consumed. But as new research from Stanford University reveals, the science of alcohol consumption is increasingly at odds with the romance

Between 2021 and 2023, cannabis use among Americans 65 and older went up 46%, according to a study published in JAMA Internal Medicine. Crawley said those numbers reflect that marijuana is a "good solution to a lot of medicinal issues." And with cannabis now legal in 40 states for medical use and 24 for recreational, according to the National Conference of State Legislatures, the stigma is quickly diminishing.

This is one of the first studies to show that even small differences in blood pressure at age seven - whether systolic or diastolic - can have long-term consequences,

Women with type 2 diabetes should consider switching their HRT tablets to patches to reduce their risk of potentially fatal blood clots, according to a new study. Researchers have found women with the condition who take an oral form of HRT have double the risk of a pulmonary embolism - when a blood clot blocks an artery in the lung - than those using skin patches. They also have a 21 per cent increased risk of heart disease, the study revealed.

A new drug baxdrostat can significantly lower blood pressure in these people whose levels remain dangerously high despite taking several medicines. The results of the BaxHTN study showed that after 12 weeks, patients taking baxdrostat saw their blood pressure fall by about 9-10 mmHg (millimetres of mercury, the unit of measurement of blood pressure) more than the placebo a reduction large enough to cut cardiovascular risk.

Measuring Lp(a) can help identify someone who should be paying more attention to their cardiovascular risks, leveraging personal genetics for better health assessments.